Septerna (NASDAQ:SEPN – Free Report) had its price objective raised by JonesTrading from $43.00 to $62.00 in a research report released on Thursday,Benzinga reports. The brokerage currently has a buy rating on the stock.
A number of other analysts have also recently weighed in on SEPN. Stifel Nicolaus set a $49.00 price objective on shares of Septerna in a research note on Tuesday. Wells Fargo & Company raised their target price on shares of Septerna from $48.00 to $50.00 and gave the company an “overweight” rating in a research note on Wednesday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Septerna in a report on Friday, July 17th. Guggenheim boosted their target price on shares of Septerna from $45.00 to $51.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Truist Financial upped their price target on shares of Septerna from $35.00 to $43.00 and gave the company a “buy” rating in a report on Wednesday, July 1st. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Septerna currently has a consensus rating of “Moderate Buy” and a consensus target price of $51.33.
Get Our Latest Stock Report on Septerna
Septerna Stock Performance
Septerna (NASDAQ:SEPN – Get Free Report) last announced its earnings results on Monday, August 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.14. Septerna had a negative return on equity of 9.57% and a negative net margin of 24.51%.The firm had revenue of $26.75 million during the quarter, compared to analysts’ expectations of $19.22 million. On average, analysts forecast that Septerna will post -1.36 EPS for the current fiscal year.
Insider Transactions at Septerna
In related news, insider Samira Shaikhly sold 11,798 shares of the business’s stock in a transaction on Tuesday, May 26th. The shares were sold at an average price of $30.06, for a total transaction of $354,647.88. Following the transaction, the insider owned 793 shares of the company’s stock, valued at approximately $23,837.58. The trade was a 93.70% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, COO Elizabeth Bhatt sold 25,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $44.00, for a total transaction of $1,100,000.00. Following the transaction, the chief operating officer directly owned 174,209 shares in the company, valued at $7,665,196. This trade represents a 12.55% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 72,828 shares of company stock worth $2,684,314 over the last three months. 5.80% of the stock is currently owned by insiders.
Institutional Trading of Septerna
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Renaissance Technologies LLC acquired a new position in Septerna in the 1st quarter valued at approximately $906,000. First Light Asset Management LLC grew its holdings in shares of Septerna by 18.0% during the 1st quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after purchasing an additional 112,049 shares in the last quarter. Janus Henderson Group PLC acquired a new stake in shares of Septerna during the 1st quarter worth approximately $21,334,000. Y Intercept Hong Kong Ltd acquired a new stake in shares of Septerna during the 1st quarter worth approximately $619,000. Finally, Swiss National Bank bought a new stake in shares of Septerna during the first quarter valued at approximately $531,000.
Septerna News Summary
Here are the key news stories impacting Septerna this week:
- Positive Sentiment: HC Wainwright significantly improved its Septerna earnings outlook, reducing its projected FY2026 loss to $1.15 per share from $2.17 and its FY2027 loss to $1.41 from $3.21. The firm retained a “Buy” rating and a $60 price target, suggesting analysts expect improved financial performance. HC Wainwright forecasts strong price appreciation for Septerna
- Positive Sentiment: HC Wainwright also raised its quarterly 2026 and 2027 EPS forecasts, with projected losses narrowing across every period. The revisions indicate better-than-expected operating trends or a more favorable development outlook for the clinical-stage biotechnology company. HC Wainwright earnings estimate revisions
- Positive Sentiment: JonesTrading raised its price target from $43 to $62 and assigned a “Buy” rating, while Wells Fargo increased its target from $48 to $50 and maintained an “Overweight” rating. These actions reinforce a favorable Wall Street view following Septerna’s recent earnings beat. JonesTrading raises Septerna price target
- Positive Sentiment: Septerna’s latest quarterly results exceeded expectations: the company reported a $0.29-per-share loss versus the anticipated $0.43 loss, while revenue of $26.75 million topped the $19.22 million consensus estimate. Septerna shares rise on better-than-expected earnings
- Negative Sentiment: COO Elizabeth Bhatt sold 25,000 shares for approximately $1.1 million at an average price of $44, reducing her ownership by 12.55%. She still holds 174,209 shares, but the insider sale could weigh on sentiment—particularly after the stock’s strong recent advance. Septerna COO insider share sale
About Septerna
We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.
Featured Stories
- Five stocks we like better than Septerna
- Is Best Buy the AI Winner Hiding in the Electronics Aisle?
- Applied Materials Beat Everything but Wall Street’s Expectations for Margins
- Back From Orbit, Intuitive Machines’ Share Price Enters the Buy Zone
- Texas Roadhouse and Brinker International Have the Recipe Rivals Are Missing
Receive News & Ratings for Septerna Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Septerna and related companies with MarketBeat.com's FREE daily email newsletter.
